AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21804212 — intervention group
Group type: COMPARATOR
Intervention: Silodosin 8 mg
Number of subjects: 82
Study 21804212 — intervention group
Group type: COMPARATOR
Intervention: Silodosin 12 mg
Number of subjects: 82
Study 21804212 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 4 mg (multiple dosing)
Number of subjects: 82
Study 19699835 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-eat (RTE) cereal consumption
Number of subjects: 660
Study 19699835 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher RTE cereal consumption in boys
Number of subjects: 660
Study 19699835 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 660
Study 16404360 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 7) followed by docetaxel 100 mg/m² (arm A)
Number of subjects: 100
Study 16404360 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m² with irinotecan 200 mg/m² (arm B)
Number of subjects: 100
Study 15600582 — intervention group
Group type: EXPERIMENTAL
Intervention: Parasympathetic Nervous System (PNS) suppression due to congestive heart failure
Number of subjects: 0
Study 15600582 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic Nervous System (SNS) suppression due to primary autonomic failure
Number of subjects: 0
Study 11213074 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation for renal transplantation based on gender (female vs male)
Number of subjects: 271
Study 11213074 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation for renal transplantation based on race (Asian males vs white males)
Number of subjects: 271
Study 11213074 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation for renal transplantation based on history of noncompliance
Number of subjects: 271
Study 11213074 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation for renal transplantation based on cardiac ejection fraction
Number of subjects: 271
Study 11213074 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation for renal transplantation based on HIV infection
Number of subjects: 271
Study 11213074 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation for renal transplantation based on weight
Number of subjects: 271
Study 9516095 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate MDI (2,000 microg with Babyhaler spacer)
Number of subjects: 17
Study 9516095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 9516095 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate MDI
Number of subjects: 17
Study 8034840 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% etidocaine
Number of subjects: 20
Study 8034840 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 20
Study 8034840 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 20
Study 8034840 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 20
Study 8034840 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenalized solutions (with epinephrine 1:200,000)
Number of subjects: 20
Study 2662099 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting gas
Number of subjects: 0
Study 2662099 — intervention group
Group type: COMPARATOR
Intervention: Silicone oil
Number of subjects: 0
Study 31413008 — intervention group
Group type: EXPERIMENTAL
Intervention: Fused CT-MR imaging datasets
Number of subjects: 20
Study 31413008 — intervention group
Group type: COMPARATOR
Intervention: Uncoregistered images
Number of subjects: 20
Study 28651865 — intervention group
Group type: EXPERIMENTAL
Intervention: Echolucent plaques
Number of subjects: 894
Study 28651865 — intervention group
Group type: COMPARATOR
Intervention: Non-echolucent plaques
Number of subjects: 894
Study 24821259 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonintubated VATS under epidural anesthesia
Number of subjects: 354
Study 24821259 — intervention group
Group type: COMPARATOR
Intervention: VATS under general anesthesia with double lumen tube
Number of subjects: 354
Study 23558603 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic DPI
Number of subjects: 103
Study 23558603 — intervention group
Group type: COMPARATOR
Intervention: Diskus®
Number of subjects: 103
Study 21679322 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week guided skiing programme (IG)
Number of subjects: 22
Study 21679322 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 22
Study 19564260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum antibiotics
Number of subjects: 2659
Study 19564260 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonstudy antibiotics
Number of subjects: 2659
Study 19564260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2659
Study 16481637 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg twice weekly)
Number of subjects: 10
Study 15542236 — intervention group
Group type: EXPERIMENTAL
Intervention: Words with high-frequency first syllables
Number of subjects: 0
Study 15542236 — intervention group
Group type: COMPARATOR
Intervention: Words with low-frequency first syllables
Number of subjects: 0
Study 12776814 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiprex (Elpen, Greece) 20 mg
Number of subjects: 24
Study 12776814 — intervention group
Group type: COMPARATOR
Intervention: Renitec (Vianex, Greece) 20 mg
Number of subjects: 24
Study 11210156 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower lateral lasers for patient set-up
Number of subjects: 16
Study 8831919 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofibrate, 100 mg/day once daily
Number of subjects: 110
Study 8831919 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil, 1200 mg/day twice daily
Number of subjects: 110
Study 8831919 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofibrate and Gemfibrozil
Number of subjects: 110
Study 1314922 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil chemotactic factors measured in coronary sinus effluents from patients
Number of subjects: 6
Study 1314922 — intervention group
Group type: COMPARATOR
Intervention: Plain cardioplegic solution
Number of subjects: 6
Study 1314922 — intervention group
Group type: COMPARATOR
Intervention: Formyl‐methionyl‐leucyl‐phenylalanine (positive control)
Number of subjects: 6
Study 3893007 — intervention group
Group type: EXPERIMENTAL
Intervention: sc human growth hormone
Number of subjects: 10
Study 3893007 — intervention group
Group type: COMPARATOR
Intervention: im growth hormone therapy
Number of subjects: 10
Study 2454358 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg/day)
Number of subjects: 0
Study 2454358 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg b.i.d.)
Number of subjects: 0
Study 2454358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2454358 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 2454358 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 2454358 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 0
Study 31343094 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC-206, an oral Mnk 1/2 kinase inhibitor
Number of subjects: 0
Study 31281938 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention program (prescribed exercises three times/week for one year)
Number of subjects: 52
Study 31281938 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine physical activities for one year)
Number of subjects: 52
Study 28388888 — intervention group
Group type: EXPERIMENTAL
Intervention: NDI-U
Number of subjects: 76
Study 26048277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab (8 mg/kg IV every 2 weeks)
Number of subjects: 1020
Study 26048277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab (8 mg/kg IV every 2 weeks) + Paclitaxel (80 mg/m² on days 1, 8, and 15 of 28-day cycles)
Number of subjects: 1020
Study 26048277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1020
Study 23204513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomised controlled trial (RCT) design
Number of subjects: 0
Study 23204513 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-methods quasiexperimental evaluation
Number of subjects: 0
Study 21451004 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA prime and subunit envelope protein boost (gag and env DNA adsorbed to polylactide coglycolide microspheres followed by recombinant trimeric envelope glycoprotein in MF59 adjuvant)
Number of subjects: 0
Study 21451004 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA prime and subunit envelope protein boost
Number of subjects: 0
Study 20084841 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive education group (3 home visits focused on home environment modification)
Number of subjects: 383
Study 20084841 — intervention group
Group type: COMPARATOR
Intervention: General health education and smoking cessation advice (Control group)
Number of subjects: 383
Study 16713143 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional-dose HT (2 mg 17beta-estradiol + 1 mg NETA)
Number of subjects: 202
Study 16713143 — intervention group
Group type: COMPARATOR
Intervention: Low-dose HT (1 mg 17beta-estradiol + 0.5 mg NETA)
Number of subjects: 202
Study 16713143 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg)
Number of subjects: 202
Study 16713143 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg)
Number of subjects: 202
Study 15757308 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserving and reinfusing 24% of calculated circulating blood volume (CBV) of autoblood
Number of subjects: 61
Study 15757308 — intervention group
Group type: COMPARATOR
Intervention: Reserving and reinfusing 12% of calculated circulating blood volume (CBV) of autoblood
Number of subjects: 61
Study 11282903 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary insulin infusion
Number of subjects: 26
Study 9272389 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole alone
Number of subjects: 22
Study 9272389 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole plus amoxicillin
Number of subjects: 22
Study 9272389 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study 7933686 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐MAG3
Number of subjects: 0
Study 7933686 — intervention group
Group type: COMPARATOR
Intervention: 123I‐OIH
Number of subjects: 0
Study 3060612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (200-300 mg/day)
Number of subjects: 140
Study 3060612 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (100-150 mg/day)
Number of subjects: 140
Study 3060612 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen (200-300 mg/day) and Indomethacin (100-150 mg/day)
Number of subjects: 140
Study 31615467 — intervention group
Group type: EXPERIMENTAL
Intervention: EmpaTeach intervention
Number of subjects: 2000
Study 31615467 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 2000
Study 27922028 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone (48 mcg per day)
Number of subjects: 76
Study 27922028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 27922028 — intervention group
Group type: COMPARATOR
Intervention: Lubiprostone and Placebo
Number of subjects: 76
Study 25452054 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondhand tobacco smoke (SHS) prevention program based on the Health Belief Model (HBM)
Number of subjects: 100
Study 25452054 — intervention group
Group type: COMPARATOR
Intervention: Standard government-mandated counseling care
Number of subjects: 100
Study 22731632 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% chlorhexidine (CHX) dental varnish
Number of subjects: 367
Study 22731632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study 21218307 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent methadone treatment
Number of subjects: 144
Study 21218307 — intervention group
Group type: EXPERIMENTAL
Intervention: Further education
Number of subjects: 144
Study 21218307 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment
Number of subjects: 144
Study 21218307 — intervention group
Group type: EXPERIMENTAL
Intervention: Fewer relationship disruptions
Number of subjects: 144
Study 21218307 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for depression
Number of subjects: 144
Study 21218307 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills for avoiding and refusing drugs, coping with stress, and maintaining recovery-supportive friendships
Number of subjects: 144
Study 19769830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 0
Study 19769830 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen/codeine 600/60 mg
Number of subjects: 0
Study 17027436 — intervention group
Group type: EXPERIMENTAL
Intervention: Oily fish (4.5 g eicosapentaenoic acid + docosahexanoic acid)
Number of subjects: 142
Study 17027436 — intervention group
Group type: COMPARATOR
Intervention: White fish (0.7 g eicosapentaenoic acid + docosahexanoic acid)
Number of subjects: 142
Study 17027436 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 142
Study 12717871 — intervention group
Group type: COMPARATOR
Intervention: Asthma medication including inhaled salbutamol 200 microg four times a day and budesonide 400 microg twice a day for 6 weeks
Number of subjects: 30
Study 12717871 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma medication plus antireflux therapy including oral omeprazole 20 mg once a day and domperidone 10 mg three times a day for 6 weeks
Number of subjects: 30
Study 11157692 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 1 g/kg on days 1 and 2 and 0.4 g/kg on days 14 and 28
Number of subjects: 59
Study 11157692 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 59
Study 11157692 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 59
Study 9159358 — intervention group
Group type: EXPERIMENTAL
Intervention: Inversion-recovery technique to map T1 transversely at the level of the basal ganglia
Number of subjects: 50
Study 9159358 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood (mean age 7.1 +/- 1.4) to adolescence (mean age 13.5 +/- 2.6)
Number of subjects: 50
Study 9159358 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescence (mean age 13.5 +/- 2.6) to adulthood (mean age 26.5 +/- 3.4)
Number of subjects: 50
Study 9159358 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression analysis
Number of subjects: 50
Study 7903211 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertatolol (5 mg)
Number of subjects: 8
Study 7903211 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertatolol (5 mg) and Prazosin (1 mg)
Number of subjects: 8
Study 7903211 — intervention group
Group type: COMPARATOR
Intervention: Prazosin (1 mg)
Number of subjects: 8
Study 3425213 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg FDDF
Number of subjects: 20
Study 3425213 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg FDDF
Number of subjects: 20
Study 3425213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31158110 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus cognitive behavioral therapy
Number of subjects: 22
Study 28479170 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive risk-reduction surgery (hysterectomy plus bilateral salpingo-oophorectomy or BSO alone)
Number of subjects: 85
Study 28479170 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive risk-reduction surgery
Number of subjects: 85
Study 28479170 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of occult cancer
Number of subjects: 85
Study 25787915 — intervention group
Group type: EXPERIMENTAL
Intervention: bortezomib/cyclophosphamide/dexamethasone (VCD)
Number of subjects: 504
Study 25787915 — intervention group
Group type: COMPARATOR
Intervention: bortezomib/doxorubicin/dexamethasone (PAd)
Number of subjects: 504
Study 23978275 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative education seminar and standard information brochure
Number of subjects: 204
Study 23978275 — intervention group
Group type: COMPARATOR
Intervention: Standard information brochure
Number of subjects: 204
Study 21255627 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% whey protein beverage (5 g, 93 kJ)
Number of subjects: 50
Study 21255627 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% whey protein beverage (10 g, 178 kJ)
Number of subjects: 50
Study 21255627 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% whey protein beverage (20 g, 348 kJ)
Number of subjects: 50
Study 19505883 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy plus CRT
Number of subjects: 813
Study 19505883 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 813
Study 17321570 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (200 microg PM(2.5)/m(3))
Number of subjects: 13
Study 17321570 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (control)
Number of subjects: 13
Study 17321570 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (100 microg PM(2.5)/m(3))
Number of subjects: 13
Study 17321570 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (0 microg PM(2.5)/m(3))
Number of subjects: 13
Study 15465230 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented external fixation
Number of subjects: 50
Study 15465230 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous pinning and casting
Number of subjects: 50
Study 11505534 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (Cardura)
Number of subjects: 36
Study 11505534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 9427903 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin A therapy
Number of subjects: 0
Study 8487050 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy and carmustine (BCNU)
Number of subjects: 778
Study 3301079 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg intravenous dose of captopril
Number of subjects: 5
Study 3301079 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg intravenous dose of captopril
Number of subjects: 5
Study 3301079 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg intravenous dose of captopril
Number of subjects: 5
Study 3301079 — intervention group
Group type: COMPARATOR
Intervention: Vehicle of captopril (control)
Number of subjects: 5
Study 31950979 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C (1.5 g every 6 hours), hydrocortisone (50 mg every 6 hours), and thiamine (200 mg every 12 hours)
Number of subjects: 216
Study 31950979 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydrocortisone (50 mg every 6 hours) alone
Number of subjects: 216
Study 29134571 — intervention group
Group type: EXPERIMENTAL
Intervention: goal‐ and learner‐centered video (GLV)
Number of subjects: 110
Study 29134571 — intervention group
Group type: COMPARATOR
Intervention: traditional video (TV)
Number of subjects: 110
Study 29134571 — intervention group
Group type: COMPARATOR
Intervention: written text (WT)
Number of subjects: 110
Study 27832548 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.4% maltodextrin solution with sweetener (CHO)
Number of subjects: 18
Study 27832548 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste-matched placebo (PLA)
Number of subjects: 18
Study 27832548 — intervention group
Group type: COMPARATOR
Intervention: Water (WAT)
Number of subjects: 18
Study 24374357 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonophoresis (PP) with capsaicin treatment and exercises
Number of subjects: 61
Study 24374357 — intervention group
Group type: COMPARATOR
Intervention: Placebo PP with capsaicin and exercises
Number of subjects: 61
Study 24374357 — intervention group
Group type: COMPARATOR
Intervention: Exercises only
Number of subjects: 61
Study 22428427 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative monitoring (judging words as negative)
Number of subjects: 0
Study 22428427 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive monitoring (judging words as positive)
Number of subjects: 0
Study 20185612 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Assistant Coaching (MAC)
Number of subjects: 100
Study 20185612 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 100
Study 20185612 — intervention group
Group type: COMPARATOR
Intervention: No Contact Control (NCC)
Number of subjects: 100
Study 19020160 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine infusion above the fascia (group AF, n = 29)
Number of subjects: 62
Study 19020160 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine infusion below the fascia (group BF, n = 31)
Number of subjects: 62
Study 15897784 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol therapy (group 1)
Number of subjects: 58
Study 15897784 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (group 2)
Number of subjects: 58
Study 11821265 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 32
Study 11821265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 10510147 — intervention group
Group type: EXPERIMENTAL
Intervention: ER1Tab
Number of subjects: 12
Study 10510147 — intervention group
Group type: EXPERIMENTAL
Intervention: ER2Tab
Number of subjects: 12
Study 10510147 — intervention group
Group type: EXPERIMENTAL
Intervention: ER3Caps
Number of subjects: 12
Study 10510147 — intervention group
Group type: COMPARATOR
Intervention: LR
Number of subjects: 12
Study 1280862 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (5,000 IU i.v.)
Number of subjects: 12
Study 1280862 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172 (3,250 anti‐Xa units i.v.)
Number of subjects: 12
Study 1280862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6703348 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 2 mg
Number of subjects: 40
Study 6703348 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 5 mg
Number of subjects: 40